Evidence has shown that METTL14 promotes m6A-dependent degradation of PDCD1 mRNA, thereby downregulating PD-1 expression, sustaining CD8+ T cell activation, and suppressing tumor progression. The gene discussed is CD8A; the disease is neoplasm.